title: Serum leptin and ghrelin levels in premenopausal women with stable body mass index during treatment of thyroid dysfunction.
abstract: BACKGROUND
  There are potentially complex interrelationships between thyroid function, leptin, ghrelin, body mass index (BMI), and percentage of body fat (%BF). The goal of this study was to determine if normalization of thyroid status in premenopausal women with hyperthyroidism and hypothyroidism would be associated with changes in serum leptin and ghrelin in the absence of thyroid dysfunction treatment-associated changes in BMI and %BF.
  
  
  METHODS
  The study was carried out in 47 selected premenopausal women: 17 with hyperthyroidism, 11 with hypothyroidism, and 19 healthy individuals who constituted the control group. Patients with thyroid dysfunction were selected for study if their BMI and %BF did not change after treatment of thyroid dysfunction. Subjects in the control group were selected on the basis of the age, BMI, and the %BF characteristics of the patients with thyroid dysfunction. Concentrations of free thyroxine (fT4), free triiodothyronine (fT3), thyrotropin, leptin, and ghrelin in serum were determined before and after treatment of thyroid dysfunction and in the control group.
  
  
  RESULTS
  Serum leptin concentrations were similar in patients with hyperthyroidism and hypothyroidism before treatment and in normal subjects and did not change significantly after treatment of hyperthyroidism or hypothyroidism. Serum ghrelin concentrations were lower in patients with hyperthyroidism, and higher in patients with hypothyroidism than in the control group (hypothyroidism = 2345 (1157-7015) [median (range)], hyperthyroidism = 1205 (438-2914), control = 2398 (1542-4920), p < 0.05).
  
  
  CONCLUSIONS
  In premenopausal women with hyperthyroidism or hypothyroidism, treatment of thyroid dysfunction that is not associated with changes in BMI or %BF does not influence serum leptin but does affect serum ghrelin. Thyroid status itself, in the absence of alterations in the BMI and %BF, has an important influence on circulating ghrelin but not leptin.
authors.affiliation: Department of Radiation Oncology, Hospital of St. Leszczynski, ul. Raciborska 26, Katowice, Poland. braclik@o2.pl
authors.forename: Mariusz
authors.initials: M
authors.lastname: Braclik
authors.forename: Czesław
authors.initials: C
authors.lastname: Marcisz
authors.forename: Sebastian
authors.initials: S
authors.lastname: Giebel
authors.forename: Arkadiusz
authors.initials: A
authors.lastname: Orzeł
mesh_terms: D000293:Adolescent; D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D015992:Body Mass Index; D005260:Female; D054439:Ghrelin / Q000097:blood*; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000188:drug therapy*; D007037:Hypothyroidism / Q000097:blood / Q000188:drug therapy*; D020738:Leptin / Q000097:blood*; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D017698:Postmenopause; D013974:Thyroxine / Q000097:blood / Q000627:therapeutic use; D014284:Triiodothyronine / Q000097:blood
chemical_list: D013956:Antithyroid Agents; D054439:Ghrelin; D020738:Leptin; D014284:Triiodothyronine; D008713:Methimazole; D013974:Thyroxine